[Scalable – Low Volume, High Value – Pipeline for New Products]

Our client has been at the forefront of sample preparation innovation for over two decades, supporting proteomics and biomarker discovery across research and clinical labs. It was the first to develop synthetically derived bead-based separations not reliant on immuno-affinity. This enabled simple bind-wash-elute workflows to differentiate sub-proteomes. These innovations paved the way for a market shift away from antibody-based to synthetic bead-based depletion methods.

The Company’s specialized products address critical challenges in sample enrichment and analysis, enhancing data quality, streamlining workflows, and improving efficiency for life sciences and biotech companies. Its products are used by major CROs, Clinical Labs, distributors, and research organizations in studies involving cancer, infectious diseases, diabetes, neurodegenerative disorders, and food and environmental safety. Cited in over 150 journal publications, the products are protected by proprietary formulations. The founder is eager to expand the product line with next-generation innovations.

Advancing Targeted Proteome Enrichment
-------------
The Company’s chemistry platform presents an opportunity to enhance efficiency and productivity in proteomic workflows through precise sub-proteome enrichment. Researchers can leverage specialized bead chemistries tailored to specific applications, while further process refinements, such as buffer optimization, will streamline workflows, reduce acquisition time, and improve cost-effectiveness.

Comprehensive & Scalable Product Line
-------------
The Company offers a suite of high-performance sample preparation products with broad utility across proteomics, genomics, and metabolomics. Designed for compatibility with LC-MS and other advanced analytical platforms, its products enable:
- Biomarker discovery and validation
- Selective enrichment and depletion
- Protein characterization and analysis
- Applications in cell biology and molecular assays
These solutions are reliable, easy to integrate, and scalable for research and clinical workflows.

Proprietary Technologies For Precision Medicine
-------------
The Company’s platforms reduce analytical bias and simplify complex proteomes by enabling:
- Enrichment of low-abundance proteins
- Depletion of high-abundance proteins
- Functional protein profiling beyond abundance-based biomarkers
This approach aligns with the growing emphasis on precision medicine and deep phenotyping, making it an essential tool in modern biomarker development.

High-Value, Low Volume Manufacturing
-------------
With proprietary IP and a simple manufacturing process, the Company produces stable, high-margin products that require minimal space—just 1,000 square feet—to house production and inventory. Gross margins are approximately 90%, with EBITDA margins over 30%.

Experienced Leadership & Continuity
-------------
The founder, a Ph.D. scientist with prior experience at major pharmaceutical firms, developed the Company’s core technologies and is open to a consulting role and contributing new ideas. The VP of Business Development, a co-founder with deep product and customer knowledge, is also available to continue post-transaction, as are the office manager and technician.

Significant Growth Opportunity
-------------
With rising demand for efficient LC-MS workflows and proteomic tools in drug and diagnostic development, the Company is well-positioned for expansion. A strategic acquirer with existing sales channels or a larger marketing footprint can significantly scale revenue and broaden market reach.

Reason for Sale
-------------
After years of innovation and steady growth, the founder is ready to transition the business to a new owner with greater resources. The sale is motivated by a desire to spend more time with family and enable the Company to reach its full potential under new leadership.